Advancements in COPD Management: Singapore’s HSA Approves Revefenacin (Yupelri®)By KayeNovember 16, 20210 Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease characterised by irreversible airflow limitation and associated with significant…
IXORA trial: Comparison Between Ixekizumab and Guselkumab for Plaque PsoriasisBy Sian LinNovember 12, 20210 The IXORA trial is a head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis. Watch the video…
Vyzulta’s “Space Race”: A New Drug for the Reduction of Intraocular PressureBy KayeNovember 4, 20210 Glaucoma is a prominent cause of irreversible blindness, with a global prevalence of 3.45% among individuals between 40-80 years of…
